-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual General and Administrative Expense history and growth rate from Q4 2017 to Q4 2024.
- Allogene Therapeutics, Inc. General and Administrative Expense for the quarter ending December 31, 2024 was $15.5M, a 9.91% decline year-over-year.
- Allogene Therapeutics, Inc. General and Administrative Expense for the twelve months ending December 31, 2024 was $65.2M, a 9.02% decline year-over-year.
- Allogene Therapeutics, Inc. annual General and Administrative Expense for 2024 was $65.2M, a 9.02% decline from 2023.
- Allogene Therapeutics, Inc. annual General and Administrative Expense for 2023 was $71.7M, a 9.62% decline from 2022.
- Allogene Therapeutics, Inc. annual General and Administrative Expense for 2022 was $79.3M, a 7.02% increase from 2021.
General and Administrative Expense, Trailing 12 Months (USD)
General and Administrative Expense, Quarterly (USD)
General and Administrative Expense, YoY Quarterly Growth (%)